Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 179

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 461 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Status: Active
Location: 236 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 481 locations
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Status: Active
Location: 145 locations
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Status: Active
Location: 129 locations
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Status: Active
Location: 58 locations
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Status: Active
Location: 22 locations
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Status: Active
Location: 21 locations
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Status: Active
Location: 15 locations
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Status: Active
Location: 15 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 16 locations
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Status: Active
Location: 15 locations
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Status: Active
Location: 12 locations
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Status: Active
Location: 10 locations
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Status: Active
Location: 10 locations
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Status: Active
Location: 9 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced and/or Node Positive Urothelial Cancer, The EV-ECLIPSE Trial
Status: Active
Location: 8 locations
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Status: Active
Location: 9 locations
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Status: Active
Location: 8 locations
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Status: Active
Location: 8 locations
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Status: Active
Location: 9 locations
A Study of 2141-V11 for the Treatment of Bladder Cancer
Status: Active
Location: 7 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Status: Active
Location: 8 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Status: Active
Location: 8 locations
Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status: Active
Location: 7 locations